Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · IMPACT BIOMEDICAL INC. (IBO)

Impact Biomedical announces F-4 filing for merger with Zoar Limited

Neutral Impact 4 of 5 m&a Written later

Impact Biomedical said a Form F-4 registration statement for its proposed merger with Zoar Limited was filed with the SEC on September 10, 2026, and announced it on September 16, 2026. The filing is a step toward closing, which remains subject to SEC effectiveness, Impact stockholder approval, and NYSE American approval of the listing of PubCo shares.

Key points

  • Form F-4 registration statement filed with the SEC on Thursday, September 10, 2026, by Zoar Limited (PubCo)
  • Closing is subject to SEC effectiveness, Impact stockholder approval, and NYSE American listing approval
  • Combined company expected to be a pharmaceutical company focused on Active Pharmaceutical Ingredients and intermediates

The filing

CompanyIMPACT BIOMEDICAL INC. (IBO)
Form8-K, current report
Filed with the SECSep 16, 2026, 6:05 PM ET
Accession number0001493152-26-042975

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:45 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 16, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.